낫적혈구병 환자에게 투여된 Inclacumab의 장기 안전성을 평가하기 위한 연구
Inclacumab 임상 시험에 참여한 낫적혈구병 환자에게 투여된 Inclacumab의 장기 안전성을 평가하기 위한 공개 확장 연구
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.
All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Enugu, 나이지리아, 460000
- University of Nigeria Teaching Hospital
-
Kaduna, 나이지리아, 800212
- Barau Dikko Teaching Hospital/Kaduna State University
-
Kano, 나이지리아, 700223
- Aminu Kano Teaching Hospital
-
Lagos, 나이지리아, 100254
- Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
-
-
Cross River State
-
Calabar, Cross River State, 나이지리아, 540242
- University of Calabar Teaching Hospital
-
-
Federal Capital Territory
-
Abuja, Federal Capital Territory, 나이지리아, 900211
- National Hospital Abuja
-
Gwagwalada, Federal Capital Territory, 나이지리아, 902101
- University of Abuja Teaching Hospital
-
-
Kaduna State
-
Zaria, Kaduna State, 나이지리아, 810105
- Ahmadu Bello University Teaching Hospital
-
-
-
-
Beirut
-
Hamra, Beirut, 레바논
- American University of Beirut Medical Center
-
-
North Lebanon
-
Tripoli, North Lebanon, 레바논
- Nini Hospital
-
-
-
-
Alabama
-
Mobile, Alabama, 미국, 36604
- University of South Alabama Children's and Women's Hospital
-
Mobile, Alabama, 미국, 36604
- Strada Patient Care Center, Pediatric Hematology
-
Mobile, Alabama, 미국, 36606
- South Alabama Medical Science Foundation
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72202
- Arkansas Children's Hospital
-
-
California
-
Orange, California, 미국, 92868
- UC Irvine Medical Center
-
-
Connecticut
-
Farmington, Connecticut, 미국, 06030
- UConn-Neag Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- University of Illinois Hospital and Health Sciences System (UI Health)
-
Chicago, Illinois, 미국, 60612
- University of Illinois at Chicago (UIC) Clinical Research Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, 미국, 02215
- Dana-Farber Cancer Institute IDS Pharmacy
-
Boston, Massachusetts, 미국, 02115
- Brigham And Woman's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan Hospitals - Michigan Medicine
-
-
New York
-
The Bronx, New York, 미국, 10461
- Jacobi Medical Center
-
-
North Carolina
-
Durham, North Carolina, 미국, 27705
- Duke University Medical Center
-
Durham, North Carolina, 미국, 27710
- DUMC Investigational Drug Services Pharmacy
-
-
Texas
-
Houston, Texas, 미국, 77030
- McGovern Medical School at UTHealth
-
Houston, Texas, 미국, 77030
- UT Physicians Comprehensive Sickle Cell Center Houston
-
Houston, Texas, 미국, 77030
- UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
-
-
-
-
-
Rio de Janeiro, 브라질, 20211-030
- Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
-
São Paulo, 브라질, 08270-070
- Casa de Saude Santa Marcelina
-
São Paulo, 브라질, 01232-010
- Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
-
São Paulo, 브라질, 08270-120
- CEPEC-Centro de Pesquisa Clinica
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, 브라질, 41253-190
- Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
-
-
Pernambuco
-
Recife, Pernambuco, 브라질, 50070-460
- Multihemo Servicos Medicos S/A
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
- Hospital de Clínicas de Porto Alegre
-
-
São Paulo
-
Ribeirão Preto, São Paulo, 브라질, 14051-140
- Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
-
São José do Rio Preto, São Paulo, 브라질, 15090-000
- Fundação Faculdade Regional de Medicina de São José do Rio Preto
-
-
-
-
Southern
-
Jizan, Southern, 사우디 아라비아, 82943
- Prince Mohammed bin Nasser Hospital
-
-
-
-
-
Muscat, 오만, 123
- Sultan Qaboos University Hospital
-
-
-
-
-
Eldoret, 케냐, 30100
- International Cancer Institute
-
Nairobi, 케냐, 00100
- Gertrude's Children's Hospital
-
Nairobi, 케냐, 00100
- Kenya Medical Research Institute - Centre for Respiratory Disease Research
-
Nairobi, 케냐, 00200
- Strathmore University CREATES
-
-
Siaya County
-
Kisumu, Siaya County, 케냐, 40600
- KEMRI/CRDR Siaya Clinical Research Annex
-
-
-
-
Atlántico
-
Barranquilla, Atlántico, 콜롬비아, 080020
- Clinica de la Costa Ltda.
-
-
Cesar Department
-
Valledupar, Cesar Department, 콜롬비아, 200001
- Sociedad de Oncología y hematología del Cesar
-
-
-
-
-
Dar es Salaam, 탄자니아, 11101
- National Institute for Medical Research (NIMR)
-
-
-
-
-
Adana, 터키 (Türkiye), 01130
- Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
-
Adana, 터키 (Türkiye), 01250
- Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
-
Ankara, 터키 (Türkiye), 06430
- Hacettepe University Ihsan Dogramaci Children Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Participants who meet all the following criteria will be eligible for study enrollment:
-
Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.
-
Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.
-
Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.
Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.
-
If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.
-
Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.
Exclusion Criteria:
Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:
- Female participant who is breastfeeding or pregnant.
- Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
- Participant withdrew consent from the originating inclacumab clinical study.
- Participant was lost to follow-up from the originating inclacumab clinical study.
- Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Inclacumab 30 mg/kg
Inclacumab 30 mg/kg administered intravenously (IV) |
Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
기간: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs. |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Annualized Rate of Vaso-occlusive Crises (VOCs)
기간: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
기간: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Number of Inpatient Hospitalization Days for a VOC
기간: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of SCD-related Urgent Care Visits
기간: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
기간: From first dose of study treatment (Day 1) up to Week 48
|
The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure. |
From first dose of study treatment (Day 1) up to Week 48
|
|
Annualized Rate of Complicated VOCs
기간: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of Red Blood Cell (RBC) Transfusions
기간: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- GBT2104-133
- 2020-005289-32 (EudraCT 번호)
- C5361003 (기타 식별자: Alias Study Number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .